Other news to note
Xortx Pharma Corp., of Calgary, Alberta, said it completed a reverse merger with Apac Resources Inc., with the resulting company, Xortx Therapeutics Inc., to focus on developing therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid, including type 2 diabetic nephropathy, cardiovascular disease and diabetes.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.